Tempus has sent de-identified tumor profiles with limited associated clinical information from more than 3,000 cancer diagnoses to the NCI.
The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
